Level Four Advisory Services’s Unity Biotechnology UBX Stock Holding History

Level Four Advisory Services’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,171	Closed	-$54K	–	637
2021 Q2	$54K	Hold	1,171	–	–	﹤0.01%	636
2021 Q1	$70K	Sell	1,171 -338	-22%	-$23K	0.01%	624
2020 Q4	$79K	Hold	1,509	–	–	0.01%	583
2020 Q3	$52K	Hold	1,509	–	–	﹤0.01%	534
2020 Q2	$132K	Hold	1,509	–	–	0.01%	552
2020 Q1	$89K	Hold	1,509	–	–	0.01%	472
2019 Q4	$108K	Hold	1,509	–	–	﹤0.01%	552
2019 Q3	$92K	Buy	+1,509	New	+$107K	0.01%	492

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Level Four Advisory Services's UBX Position: Q3 2021 in Review

Level Four Advisory Services sold out of Unity Biotechnology (UBX) in Q3 2021, closing a stake of 1,171 shares — an estimated $54K sold.

Level Four Advisory Services first reported a position in UBX in Q3 2019 and held it in 8 quarters. The position peaked at $132K in Q2 2020. 84 funds tracked by Wall St. Rank hold UBX as of Q3 2021.

Level Four Advisory Services reported no remaining Unity Biotechnology position as of Q3 2021 after selling out during the quarter.
Level Four Advisory Services sold 1,171 Unity Biotechnology shares in Q3 2021, an estimated $54K.
Level Four Advisory Services first reported a position in Unity Biotechnology in Q3 2019 and held it in 8 quarters.
Level Four Advisory Services's Unity Biotechnology position peaked at $132K in Q2 2020.
84 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2021.

Based on Level Four Advisory Services's 13F filing for Q3 2021, filed 12 Oct 2021.